David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...

The big pharma sector is one that’s generally fallen out of favor for many investors over the past few decades, as large ...

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 earnings figures before ...

Pharmaceutical company Eli Lilly (LLY) has been raking it in lately thanks to its two flagship products: Mounjaro and Zepbound. These two have ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Novo Nordisk only prices in management's latest year guidance and underestimates the full market potential. See why I rate ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.DozQrLpG.js ...

Eli Lilly and Company (NYSE:LLY – Get Free Report)’s share price dropped 0.2% during mid-day trading on Tuesday after Citigroup lowered their price target on the stock from $1,250.00 to $1,190.00.

Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-one brokerages that are presently covering the stock, ...

Given recent price action, a buy-the-dip scenario ... up almost 250% while generating $1.5 per share in dividends. I’ve been bullish on Eli Lilly for a while, and the recent pullback makes ...

The company's simple, shareholder- and customer-first ethos is delivering not only stellar revenue growth, but immense triple digit GAAP and non-GAAP earnings per share growth. There are other ...

The share prices of Eli Lilly and Novo Nordisk, leading stocks in obesity treatment, have been fluctuating, resulting in poor performance for the exchange-traded funds (ETFs) that heavily ...